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ABSTRACT
Objective The aim of this study was to assess the 
marketing status of the new paediatric medicinal products 
listed in the 10- year report as initially authorised between 
2007 and 2016, reflecting the product availability in four 
Nordic countries.
Design This is a cross- sectional study.
Setting Analysis of the national medicine agency’s 
databases in Denmark, Finland, Norway and Sweden.
Data source New medicinal products with paediatric 
indications and new paediatric formulations listed in the 
Annex of European Medicines Agency’s EU Paediatric 
Regulation 10- year report.
Data analysis The products were classified according 
to national marketing status between January 2019 and 
March 2019, whether a product was authorised and 
whether the product was marketed.
Main outcome measures The percentages of the 
new medicinal products with paediatric indications and 
new paediatric formulations having a valid marketing 
authorisation and being marketed, both in terms of the 
sums of all countries and separately for each country.
Results Across the four countries, 21%–32% (16/76–
24/76) of the new medicinal products were not marketed. 
Of the new formulations relevant to children, 29%–50% 
(16/56–28/56) were not marketed, and a significant 
proportion of these products had never been marketed.
Conclusions This study reflects the reality of the 
implementation of the Paediatric Regulation. The results 
show that several new paediatric medicines and new 
formulations are not marketed. This affects the product 
availability. Similar data from other countries are needed 
to evaluate the overall European status to find remedies 
to current situation and increase the availability of the 
medicines for children.
INTRODUCTION
The benefit of new therapies has not reached 
children to the same extent as the adult 
population throughout the history of drug 
development. Children still lack medicines 
across many therapeutic areas and all age 
groups, as well as age- appropriate formu-
lations, adequate dosing and administra-
tion instructions in the product labelling. 
Increased knowledge and revised attitudes 
have prompted practical actions to improve 
the situation in the form of new legislation. 
In Europe, the Paediatric Regulation (EU 
1901/2006 and 1902/2006) was implemented 
on 26 January 2007.1
The aim of the Paediatric Regulation is to 
improve the health of children in Europe by 
facilitating the development and availability 
of medicines for children. To achieve this, the 
regulation includes a system of obligations, 
rewards and incentives for the pharmaceu-
tical industry. It applies to all new medicines 
aiming for a Marketing Authorisation (MA) 
What is known about the subject?
 ► The aim of the Paediatric Regulation (EU 1901/2006) 
is to improve the health of children by facilitat-
ing the development and availability of paediatric 
medicines.
 ► In 2017, the European Medicines Agency published 
a 10- year report, and concluded that a significant 
number of new medicines for children have been 
authorised.
 ► Marketing authorisation is no guarantee that a new 
medicine is available for all patients, as the accessi-
bility to medicines varies across countries.
What this study adds?
 ► 21%–32% (16/76–24/76) of the new medicines 
initially authorised for children between 2007 and 
2016 were not marketed across the four Nordic 
countries.
 ► 29%–50% (16/56–28/56) of the new paediatric for-
mulations were not marketed and a significant pro-
portion had never been marketed.
 ► Despite the intentions of the EU’s Paediatric 
Regulation, medicines targeted at children are not 
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in Europe, as well as to authorised, patent- protected 
medicines, when these are developed with new indica-
tions, routes of administration or pharmaceutical forms 
for children. In these cases, the company must make a 
development plan for the product (paediatric investiga-
tion plan, PIP), which must be agreed on by the Euro-
pean Medicines Agency’s (EMA) Paediatric Committee.2 
For older off- patent products, the regulation offers a new 
Paediatric- Use Marketing Authorisation status for the 
new paediatric- only products.
In the European Commission’s (EC) 10- year report 
in 2017 on the implementation of the Paediatric Regu-
lation,3 and the background report from EMA,4 a clear 
positive effect was demonstrated in several areas. One 
of these was the number of authorised new medicines 
for the period between 2007 and 2016. The data indi-
cated that the regulation has facilitated paediatric medi-
cine development, resulting in new products with initial 
paediatric indication, extensions of previously authorised 
products to children and new formulations or strengths 
suitable for children. All these are listed in the Annex 
(Chapter 1) to the EMA’s 10- year report.4
Safety, efficacy and quality data are required for all 
medicines seeking MA. After MA, the product can be 
placed on the market, allowing patient’s access to the 
new medicine through official commercial channels. 
However, the choice to place an authorised product on 
the market in a specific country is the decision of the MA 
holder (ie, the company). The product may be marketed 
only in selected countries, resulting in variations in ’real- 
world access’ to medicines.
Several recent reports have focused on the various devel-
opments and achievements that have followed the Paedi-
atric Regulation,5–11 but to the best of our knowledge, 
no studies have reported on the actual country- specific 
marketing status after the Paediatric Regulation imple-
mentation. The aim of this study was to assess the current 
marketing status (having MA and being marketed) of the 
new medicinal products and new formulations listed in 




No patients nor voluntary participants were involved in 
this study, so no ethics review was needed.
Data collection
The study target was to investigate the marketing status 
of new medicines for children in four Nordic countries 
during the predefined period between January 2019 
and March 2019. The term ‘marketing status’ refers to 
whether a product was authorised (having a valid MA) 
and whether the product was marketed, during the time 
of the study period, based on the regulatory classification 
of the products.
Data source
The products studied were those listed as having been 
authorised in Europe between 2007 and 2016 according 
to the Annex of the EMA’s 10- year report to the EC.4 This 
included (a) new medicinal products authorised with a 
paediatric indication at the time of the initial MA and 
(b) new formulations (ie, new pharmaceutical forms and 
strengths) relevant for children as listed in the Annex 
tables 1, 3 and 6. Information on the source data for this 
study is given in table 1.
Data were collected from the national Medicine 
Authority databases: Denmark (DK): KAT, the in- house 
administrative database in the Danish Medicines Agency; 
Finland (FI): in- house register for marketing authorisa-
tions, Fimea; Norway (NO): Athene, in- house database 
at the Norwegian Medicines Agency, version 2019.09.1.; 
and Sweden (SE): VARA, available at the Swedish eHealth 
Agency.
Table 1 The source data for this study, from the Annex of the 10- year report to the EC (EMA/35987/2016), listing new 
authorised medicines (Annex’ chapter 1)4
Annex table 
number* Tables in the Annex of EMA’S 10- year report
Number of medicinal 
products listed
1 New medicines (CAPs, initial MAs, including a paediatric indication (product group A)† 82
3 New pharmaceutical forms (or routes of administration) of paediatric relevance (CAPs, 
line extensions of existing MAs)
(product group B)
27
6 New pharmaceutical forms (or routes of administration) of paediatric relevance (NAPs, 
line extensions of existing MAs)
(product group B)
16
*Annex’ table 4, listing new nationally authorised medicines, was excluded since the majority were generic products and not new medicinal 
products. Annex’ tables 2 and 5 (new paediatric indications, variations of already authorised products) were not analysed since our focus 
was on availability of new products.
†Annex’ table 1 excludes medicines that are not subjected to the obligations of the Paediatric Regulation (eg, generics, hybrid medicines, 
biosimilars, etc).
CAPs, centrally authorised products; EC, European Commission; EMA, European Medicines Agency; MA, marketing authorisation; NAPs, 
nationally authorised products .
copyright.
 on M
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Marketing status was assessed separately for each country. 
Each medicinal product listed in the Annex tables was clas-
sified by the following two criteria: (1) having a valid MA or 
not, and (2) being marketed or not (figure 1). For the new 
formulations (product group B), if products were assessed 
as ‘not marketed’, the additional information regarding 
whether the product had ever been marketed between 
2007 and 2016 was collected, where data were available. 
This information was accessible in three (DK, FI and NO) 
national databases, and not analysed for SE.
The Paediatric Regulation may require companies to 
develop age- appropriate formulations in addition to what is 
foreseen for use in adults, specified in the agreed- upon PIP. 
To analyse whether these obligations exerted any impact on 
the marketing status of new formulations, the agreed- upon 
PIPs were assessed regarding whether the formulation was 
part of the obligations in the PIP. The new formulations 
(product group B) with an agreed- upon PIP were identified 
using the information from the EMA’s database.12
Data analysis
Results were calculated as percentages (proportions) of 
the new products which still had a valid MA and being 
marketed. Data were presented both in terms of the sums 
of all countries and separately for each country. Distribu-
tions between different therapeutic areas were identified 
according to the Anatomical Therapeutic Chemical code 
provided in the corresponding Summary of Product 
Characteristics. Descriptive tables, figures and statistics 
were created in MS Excel.
Several of the products in the source lists represent 
more than one strength or form. For new medicinal 
products (product group A), a separate assessment was 
initially performed for each strength. In the final analysis 
of these products, a new medicinal product was regarded 
as ‘marketed’ even if not all different strengths were placed 
on market. For the product group B, separate assessment 
was performed for each form or strength for the new 
formulations.
The products presented in this study by substance and 
pharmaceutical form because of possible variations in the 
product trade names between countries.
RESULTS
New centrally authorised medicinal products (product group A)
Products still having a MA and being marketed
Over 90% (76/82) of the new paediatric medicinal products 
authorised centrally between 2007 and 2016 still retained 
MA at the time of the study (Q1/2019). Out of these 76 
newly authorised medicinal products, the most common 
group was medicines for infections and vaccines (30%) 
(table 2). More than one- third (27/76) of new medicinal 
products had several strengths initially authorised, and for 
nearly all of these (23/27), all strengths were marketed.
Products not marketed
A total of six medicinal products had no longer marketing 
authorisation in the EU at the time of the study. These 
products contained gadoversetamide, rilonacept, influ-
enza vaccine (live attenuated, nasal), somatropin, lamivu-
dine/raltegravir potassium and pancreas powder. One of 
these products (gadoversetamide) was withdrawn based 
on safety signals. The reason for the withdrawal of the 
other products (N=5) is not stated in the databases used.
Nearly half of the antineoplastic and immunosup-
pressive agents were not marketed in any of the Nordic 
countries. There were additional differences between 
the countries, regarding distribution among therapeutic 
areas: in FI, 4/10 of the products in the group of bile 
enzymes, vitamins and medicines for metabolic disease 
were not marketed; conversely, in the other countries, 
the proportion was 1/10. Similarly, as much as 5/11 of 
anticoagulants, coagulation factors and other haemato-
logical agents were not marketed in FI, but in other coun-
tries, the proportion was lower: 4/11 in SE and 2/11 in 
both NO and DK (table 2).
A total of 29 medicinal products were not marketed 
in at least one of the included countries (table 3). The 
hydroxycarbamide and cholic acid products are exam-
ples of the 13 new medicinal products that were not 
marketed in any of the Nordic countries.
On average, 57/76 of the newly authorised medicinal 
products were currently being marketed in the Nordic 
countries. SE had the highest proportion (79%), followed 
by NO (78%), DK (74%) and FI (68%) (figure 2).
New formulations (product group B)
A total of 43 products represented new formulations, of 
which 27 were centrally authorised, and 16 nationally 
authorised. Five of the nationally authorised products 
were excluded due to insufficient information, rendering 
Figure 1 Flow chart illustrating how marketing status 
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it impossible to identify the exact product. The resulting 
38 products with new formulations, represented a total 
of 56 different formulations, as several strengths or forms 
were relevant for some products. Each of these 56 formu-
lations were assessed by marketing status.
Figure 3 indicates the marketing status in the various 
countries for these 56 products. In all four countries, 
the majority (91% to 95%) still had MA. However, the 
proportion of products being marketed was substantially 
lower, ranging from 50% to 71%. SE had the highest 
proportion of products marketed, and NO had the 
lowest. The proportion of marketed products was lowest 
for nationally authorised products (ranging from 38% to 
62%), showing lowest proportion in Finland.
One fourth (14/56) of the different specific formula-
tions were not marketed in any of these countries, and 
29% (16/56) were marketed in all countries. Table 4 lists 
details of the 40 formulations that were not marketed 
in one or more of the countries, having antivirals as the 
largest group of such products. Most of the new formu-
lations that were not marketed, seem never to have been 
marketed (*).
The formulations not marketed in any country were 
often the paediatric specific, such as the lower strength 
formulations (5/14), the oral liquid/powder/granules 
(5/14) and the chewable tablets (2/14). Conversely, 
approximately half of the products marketed in all 
countries were products for which the new formulation 
seemed to have replaced the old one (eg, prefilled 
syringe replacing vials, tablets replacing capsules and 
‘ready- to- use solution for injection’ replacing ‘powder 
and solvent for solution for injection’).
The majority (35/56) of the reviewed new formula-
tions represented products with agreed- upon PIPs where 
the specific formulation was part of the PIP obligations. 
Only 6 of these 35 formulations were marketed in all 
countries. Of the 14 formulations not marketed in any of 
the countries, nine were listed as specific requirements in 
the PIP. In contrast, the majority (10/16) of the formula-
tions available in all countries, did not have a PIP or were 
not included in specific PIP formulation requirements.
DISCUSSION
Our data reveal that on average 75% of the new 
paediatric medicines initially authorised for children 
(2007–2016) were still authorised and marketed. Simi-
larly, for the new paediatric formulations, 57% were 
marketed.
The reported achievements of the Paediatric Regu-
lation3 4 are optimistic, indicating increased number of 
authorised medicines for children. However, the choice 
to place an authorised product on the market in each 
country is influenced by several factors. Therefore, 
assessing the actual marketing status may add important 
piece of information regarding the medicines’ availability 
Table 2 New centrally authorised medicinal products (n=76) having MA and being marketed across different therapeutic 
areas as defined by ATC codes and number of medicinal products in DK, FI, NO and SE
Therapeutic area (ATC codes)
Total number of new 
medicinal products
Number of medical products 
being marketed
DK FI NO SE
Antibacterial, antimycotic, anti- HIV agents, vaccines and immunoglobulins 
(J01, J02, J05, J06 and J07)
23 14 17 17 18
Antineoplastic and immunosuppressive agents
(L01, L03 nd L04)
11 7 6 6 7
Anticoagulants, coagulation factors and other haematological agents (B01, 
B02 and B06)
11 9 6 9 7
Bile enzymes, vitamins and metabolic disease (A05, A11 and A16) 10 9 6 9 9
Antiepileptics, sleeping agents and mitochondrial diseases (N03, N05 and 
N06)
7 7 7 7 7
Allergy, asthmatic and cystic fibrosis agents
(R01, R03 and R07)
4 4 3 4 4
Antihypertensives and hyperlipidic agents
(C02, C07 and C10)
3 2 3 3 3
Antipoisoning agents (V03) 2 1 1 1 1
Contraceptives (G03) 1 1 1 1 1
Duchenne muscular dystrophy (M09) 1 1 1 1 1
Growth hormone (H01) 1 1 1 1 1
Topical antibiotics (D06) 1 0 0 0 1
Antimalarial agents (P01) 1 0 0 0 0
All (ATC A- V) 76 56 52 59 60
ATC, Anatomical Therapeutic Chemical; DK, Denmark; FI, Finland; MA, marketing authorisation; NO, Norway; SE, Sweden.
copyright.
 on M
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Table 3 New medicinal products having marketing authorisation (n=76) but not marketed (marked as X in the columns) in 
DK, FI, NO and SE, by therapeutic area (based from ATC code at second level, eg, B02), year and country
Therapeutic area Year Medicinal product
Products not marketed, 
marked with X
DK FI NO SE
Antihaemorrhagic 2012 Catridecacog X X
Antihaemorrhagic 2013 Human coagulation factor VIII/human von Willebrand 
factor
X X X X
Antihaemorrhagic 2016 Eftrenonacog alfa X
Antihaemorrhagic 2016 Albutrepenonacog alfa X X
Antihaemorrhagic 2016 Human coagulation factor X X X X X
Anti- infective agent for topical 
use
2007 Retapamulin X X X
Antineoplastic agent 2007 Nelarabine X
Antineoplastic agent 2007 Hydroxycarbamide X X X X
Antineoplastic agent 2016 Asparaginase X X X X
Antipoisoning agent 2007 Hydroxocobalamin X X X X
Bile and liver diseases 2014 Cholic acid X X X X
Hypertension 2013 Bosentan X
Immunoglobulins 2007 Human normal immunoglobulin (IVIG) X X X
Immunosuppressants 2009 Canakinumab X
Immunstimulating 2013 Filgrastim X X X X
Immunstimulating 2016 Autologous CD34+ enriched cell fraction that contains 
CD34+ cells transduced with retroviral vector that 
encodes for the human ADA cDNA sequence
X X X X
Malaria 2011 Dihydroartemisinin / piperaquine phosphate X X X X
Metabolic disease 2008 Sapropterin X
Metabolic disease 2014 Elosulfase alfa X
Respiratory tract disease 2012 Ivacaftor X
Vaccine 2007 Human papillomavirus vaccine (types 16–18) X X
Vaccine 2009 Pneumoccocal polysaccharide conjugate vaccine 
(absorbed)
X X
Vaccine 2012 Repandemic influenza vaccine (H5N1) (whole virion, 
inactivated and prepared in cell culture)
X X X X
Vaccine 2013 Diphtheria (d), tetanus (t), pertussis (acellular, 
component) (pa), hepatitis b (rDNA) (HBV), poliomyelitis 
(inactivated) (IPV) and haemophilus influenzae type b 
(Hib) conjugate vaccine (adsorbed)
X X
Vaccine 2013 Influenza vaccine (live attenuated, nasal) X
Vaccine 2013 Diphtheria (d), tetanus (t), pertussis (acellular, 
component) (pa), hepatitis b (rDNA) (HBV), poliomyelitis 
(inactivated) (IPV) and Hib conjugate vaccine (adsorbed)
X X X X
Vaccine 2016 Pandemic influenza vaccine (H5N1) (live attenuated, 
nasal)
X X X X
Vaccine 2016 Diphtheria, tetanus, pertussis (acellular, component), 
hepatitis b (rDNA), poliomyelitis (inactivated) and Hib 
conjugate vaccine (adsorbed)
X X X X
Vitamin 2009 Tocofersolan d- alpha tocopheryl polyethylene glycol 
succinate
X
Number of all medicinal products not marketed 20 24 17 16
ATC, Anatomical Therapeutic Chemical; DK, Denmark; FI, Finland; NO, Norway; SE, Sweden.
copyright.
 on M









jpo: first published as 10.1136/bm






6 Lepola P, et al. BMJ Paediatrics Open 2020;4:e000880. doi:10.1136/bmjpo-2020-000880
Open access
for children. Some papers have studied the availability 
of, for example, paediatric oral formulations and shown 
variability across Europe13–15 but, unfortunately, none of 
these studies have assessed the availability related to the 
reported outcome of the Paediatric Regulation.
For the new medicines initially authorised for children, 
the divergence between countries was not profound. 
These new medicines were all centrally authorised, which 
would facilitate to market these products ‘Europe- wide’, 
targeting the largest possible population throughout 
Europe.
Despite child- friendly, age- appropriate formulations 
being especially important for the youngest age groups, 
for three of the four countries only roughly half of 
the new formulations were marketed. It is notable 
that the forms or strengths that were not marketed in 
any country were often the paediatric- specific ones: 
lower strengths, oral liquids or chewable tablets. In 
contrast, a significant proportion of the new forms 
and strengths that were marketed in all countries did 
not seem to fulfil a specific paediatric need but rather 
appeared to optimise the entire product line, often 
replacing old formulations.
The reasons why products were placed on or not 
placed, or taken off the markets, were not assessed in 
this study. Intuitively, the limited size of the population 
could anticipate sparse return on investments, targeting 
only a fraction of the patients. Regulatory obligations, 
like nation- specific packages, in addition to the national 
pricing and reimbursement systems may have strong 
effect on the strategic marketing decisions. Furthermore, 
prescribing habits may play a role, particularly, if the 
established practice of off- label use has been accepted 
for decades. Finally, there might be some dissimilarities 
in the unmet therapeutic needs between the countries 
(eg, antivirals not marketed due to the smaller number 
of children affected).
The Paediatric Regulation requirements to develop 
a paediatric specific formulations, as agreed in the PIP, 
are no indicator of whether the formulation will be 
marketed. Only 17% of the new formulations agreed 
on PIP, were marketed in all four countries, and almost 
2/3 of the formulations that were not marketed in any 
country were specifically requested in the PIPs. Impor-
tantly, the reward granted through the regulation does 
not oblige the company to place a product on the market 
in all countries, but only to have MA in all member 
states. Marketing is, therefore, not specifically motivated, 
and any potential reward (ie, prolonged protection) is 
granted nationally for the full product line regardless of 
whether all paediatric- specific formulations are marketed 
in that country.
Our data indicates that most products that were not 
currently marketed had never been marketed, suggesting 
that the decision to entering a country- specific market is 
made up front. Thus, factors like actual low sale, patent 
Figure 2 Number of new medicinal products marketed (or 
not) in DK, FI, NO and SE. DK, Denmark; FI, Finland; NO, 
Norway; SE, Sweden.
Figure 3 Marketing status for new formulations of medicinal products (whether the product still had MA and was still 
marketed) per country (DK, FI, NO and SE). CAP, centrally authorised product; DK, Denmark; FI, Finland; MA, marketing 
authorisation; NAP, nationally authorised product; NO, Norway; SE, Sweden.
copyright.
 on M
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expiration or introduction of generics seem of limited 
relevance.
Strengths and limitations
In this study, a product being ‘marketed’ is interpreted 
as a surrogate measure for the product’s availability after 
it has been placed on the market, because it does not 
guarantee the access to patients. Medicines can be avail-
able for the patients even if a product is not marketed 
(eg, through special licensing or compassionate use 
programmes), and despite a product is marketed, it may 
not be available for patients (eg, reimbursement rules, 
medicine shortages or physicians not prescribing the 
product).
There are several extremely relevant factors having 
direct impact on the companies’ market strategies and 
for the decisions to placing products on markets, such 
as the targeted market size or country specific expendi-
ture, pricing and reimbursement practices. If thoroughly 
investigated, this type of additional data would give more 
detailed rationale and increase understanding for the 
current situation. However, studying these aspects would 
need the involvement of other scientific disciplines and 
other regulatory authorities.
This study did not assess the clinical consequences of 
the marketing status of each product and whether these 
products specifically fulfil a certain paediatric unmet 
need or not. For some products, alternatives might have 
been available, for others not. It is assumed that at least 
for products with a PIP obligation, such a need has been 
identified.
Some limitations were identified for the source data, 
as the nationally authorised products were reported on 
voluntary basis by National Competent Authorities and 
thus may not be complete. Additionally, for the nation-
ally authorised products, generics seem to have been 
reported extensively, which was the reason why the 
Annex’ table 4 was excluded. Nevertheless, the listed 
products are expected to represent most of the relevant 
ones authorised.
Placing a product on the market and having it marketed 
increases the potential availability, ensures access to 
national product information, provides proper follow- up 
by companies and authorities, and frequently affects the 
price regulation and therefore serves as important indi-
cator of the accessibility. This study provides a snapshot 
of the ‘real- world’ situation at a specific time point and 
will not fully reflect all the dynamic factors and processes 
related to marketing status.
While acknowledging that several factors ultimately 
impact patient ‘real- life’ access to medicines, we consider 
having a product marketed as one particularly important 
indicator of the medicine availability.
These results may not be typical for all European coun-
tries since it represents a group of relatively small coun-
tries and, as such, a market with limited financial interest. 
Therefore, similar data from other countries would be 
needed to create a better picture of the overall situation.
In conclusion, the reported success of the Paediatric 
Regulation in terms of new authorised products, is only 
partially valid. To make more sustainable future changes 
to the current situation, the ongoing EC pharma strategy, 
including the evaluation of Paediatric Regulation,16 
should consider more carefully to understand reasons 
and cure the existing hindering factors. Elements like 
targeted rewards, adapted legal requirements, an alterna-
tive pricing system and decreasing off- label use should all 
be discussed. Truly, the access to medicines for children 
is in practice still limited.
Twitter Kirstine Moll Harboe @kirstinemoll
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